piflufolastat f-18 · Aphelion · NDA 220089

Pylarify Truvu

Earliest generic entry, as listed
9 Jun 2037

Blocked by patent: US 10947197, US 11851407.

Listed patents · 6 unexpired

PatentClaimsExpires
US 10947197drug substance, drug product, use U-3317 · sets the listed date9 Jun 2037
US 11851407drug substance, drug product, use U-3317 · sets the listed date9 Jun 2037
US 8778305drug substance, drug product, use U-331721 Sep 2030
US 12070513drug substance, drug product, use U-331731 Jul 2029
US 9861713drug substance, drug product, use U-331731 Jul 2029
US 8487129drug substance, drug product7 Nov 2027

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
220089 · 001 · RLDsolution, intravenous1mCi/mL-120mCi/mL9 Jun 2037
Expired or delisted (1)
  • NCE · 26 May 2026